Answers are grounded in this paper and cite their sources.
Acidosis is a useful biomarker for tumor diagnoses and for evaluating early response to anti-cancer treatments. T1-based MRI contrast agents have been developed with a r1 relaxivity that is responsive to extracellular pH (pHe) in the tumor microenvironment. However, the concentration of these agents in the tumor must also be known to determine r1 relaxivity. We have developed PET/MRI co-agents that can be evaluated with simultaneous PET/MRI during pre-clinical studies with mouse models of human cancers. The PET agent reports on the concentration of the agents, which can be used to determine r1 relaxivity and estimate pHe in tumors.
No takes yet. Share an insight, caveat, or question.
Pollard et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: